Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Pemoline for Cocaine Abuse - 7
This study has been completed.
Sponsors and Collaborators: National Institute on Drug Abuse (NIDA)
VA Connecticut Healthcare System
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00000282
  Purpose

The purpose of this study is to evaluate the treatment of pemoline for cocaine abuse.


Condition Intervention Phase
Cocaine-Related Disorders
Drug: Pemoline
Phase II

Drug Information available for: 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- Cocaine hydrochloride Pemoline
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment
Official Title: Pemoline for Cocaine Abuse

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Side effects
  • Drug use
  • Retention

Estimated Enrollment: 0
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000282

Locations
United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
VA Connecticut Healthcare System
Investigators
Principal Investigator: Thomas R Kosten, M.D. VA Connecticut Healthcare System
  More Information

Study ID Numbers: NIDA-09250-7, P50-09250-7
Study First Received: September 20, 1999
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00000282  
Health Authority: United States: Federal Government

Study placed in the following topic categories:
Cocaine-Related Disorders
Pemoline
Mental Disorders
Substance-Related Disorders
Disorders of Environmental Origin
Cocaine

Additional relevant MeSH terms:
Therapeutic Uses
Physiological Effects of Drugs
Central Nervous System Stimulants
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009